Fresh Mission as duo are promoted to new roles
Cambridge drug discovery business Mission Therapeutics has promoted Dr Paul Thompson to CSO and Dr Nick Edmunds to CTO.
In his new role, Dr Thompson assumes responsibility for Mission’s discovery, validation and translational science activities, as well as biomarker research and target selection on novel DUBs.
He has around 18 years’ experience in translational research and early clinical development. He joined Mission as medical director for CNS in 2016 and in 2018 was promoted to VP of clinical development.
Previously, he has worked at ONO Pharma UK, where he was clinical science director, and GlaxoSmithKline, where he led global project teams as director of discovery medicine in neurology, following earlier roles leading laboratory biomarker research and experimental medicine studies.
Nick assumes responsibility for Mission’s world-leading DUB platform and chemistry, in addition to exploratory toxicology and ADME activities.
With over 15 years’ pharmaceutical industry experience, Dr Edmunds has a track record in drug discovery and early clinical development. He joined Mission as a senior director in September 2018 from AstraZeneca and was promoted later that year to VP and head of DUB discovery.
At AstraZeneca Dr Edmunds held senior roles in drug safety and metabolism, including senior director, head of new modalities and director of safety pharmacology.
Prior to that, he was a research Fellow at Pfizer Global Research and Development, US, and the cardiovascular discipline leader in global safety pharmacology at Pfizer Global Research and Development, UK.